Calidi Biotherapeutics (Calidi Biotherapeutics) Total Current Assets : $1.94 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Calidi Biotherapeutics's total current assets for the quarter that ended in Mar. 2024 was $1.94 Mil.

Calidi Biotherapeutics Total Current Assets Historical Data

The historical data trend for Calidi Biotherapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Total Current Assets Chart

Calidi Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Current Assets

0.51

2.74

0.79

4.30

Calidi Biotherapeutics Quarterly Data
	Dec20	Sep21	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial					-	2.81	11.69	4.30	1.94

Calidi Biotherapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Calidi Biotherapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1.949	+	1.36	+	0	+	0.994
	=	4.30

Calidi Biotherapeutics's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1.143	+	0	+	0	+	0.793
	=	1.94

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Calidi Biotherapeutics (AMEX:CLDI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Calidi Biotherapeutics's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.143	-	21.978	+	0.75 * 0	+	0.5 * 0
=	-20.84

Calidi Biotherapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.calidibio.com

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines

From GuruFocus

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

By ACCESSWIRE • 05-17-2024